ResMed (ASX:RMD) Accumulated Depreciation: A$-1,069 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
97 GF Score
Price A$32.51
GF Value A$36.74
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Accumulated Depreciation?

ResMed ASX:RMD +1.72% 97 Accumulated Depreciation is A$-1,069 Mil as of Jun. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 97/100 and a GF Value™ of A$36.74 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

ResMed's quarterly accumulated depreciation declined from Dec. 2025 (A$-1,126 Mil) to Mar. 2026 (A$-1,110 Mil) but then stayed the same from Mar. 2026 (A$-1,110 Mil) to Jun. 2026 (A$-1,069 Mil).

ResMed's annual accumulated depreciation declined from Jun. 2024 (A$-1,095 Mil) to Jun. 2025 (A$-1,083 Mil) but then stayed the same from Jun. 2025 (A$-1,083 Mil) to Jun. 2026 (A$-1,069 Mil).

ResMed Accumulated Depreciation Related Terms

ResMed Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for ResMed's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Accumulated Depreciation Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -900.92 -995.34 -1,094.81 -1,083.35 -1,068.67

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,083.35 -1,096.12 -1,125.68 -1,110.44 -1,068.67
ASX:RMD
97GF Score
ResMed Inc ASX:RMD
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$-1,069 Mil mean?
ResMed (ASX:RMD) has a Accumulated Depreciation of A$-1,069 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on ResMed and its competitors.
Is ResMed's Accumulated Depreciation too high?
ResMed's current Accumulated Depreciation is A$-1,069 Mil. Overall, ResMed has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Accumulated Depreciation compare to MDLN and WST?
ResMed's Accumulated Depreciation of A$-1,069 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Devices & Instruments company?
A good Accumulated Depreciation depends on the Medical Devices & Instruments industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on ResMed and its competitors. ResMed's current Accumulated Depreciation is A$-1,069 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.74, compared to a current price of A$32.51 — trading 11.5% below its estimated fair value. The current Accumulated Depreciation is A$-1,069 Mil. ResMed's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Accumulated Depreciation is A$-1,069 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$32.51 is trading 11.5% below its estimated GF Value™ of A$36.74. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for ASX:RMD:

  • Accumulated Depreciation: A$-1,069 Mil
  • GF Value™: A$36.74 vs. price of A$32.51 (11.5% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
97GF Score

Get the complete analysis for ASX:RMD

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$32.51
Price
A$36.74
GF Value